Fast, reliable, inexpensive and specific stimulation of a broad spectrum of clinically-relevant immune effector cells (CD4+, CD8+, NK and NKT-like cells) with Lophius’ T-activated® proteins.
Fields of application:
- Better T cell-based diagnostic solutions for viral infections like CMV, EBV, BKV,...
- Enhanced vaccine efficacy through improved immunogenicity of proteins
- Improved immunomonitoring due to higher assay sensitivity
Enhanced immunogenicity of proteins
In contrast to peptides and unmodified proteins, T-activated® proteins (formulated with Lophius' patented T-activation® buffer) are processed and cross-presented via the exogenous (MHC-II) and endogenous (MHC-I) pathways by functional antigen-presenting cells (APC), thus mimicking a natural infection (Figure 1).
In addition, T-activated® proteins allow a more efficient and HLA antigen-independent stimulation of a broad spectrum of clinically-relevant subpopulations of antigen-reactive effector cells (CD4+ and CD8+ T cells, NK and NKT-like cells), as outlined in Figure 2.
Advantages of T-activated® proteins:
- Enhanced immune-stimulatory capacity and immunogenicity of proteins
- Cross-presentation by APC along MHC-I and MHC-II pathways
- Closely mimicking the natural uptake, processing and presentation of antigens
- Stimulation of a broad spectrum of clinically-relevant effector cells (Th, CTL, NK, NKT-like cells)
- HLA antigen-independent stimulation
- Applicable for multiple immunological assays and read-out systems, including ELISpot, FACS and ELISA
Fields of application:
- T cell-based diagnostic solutions for viral infections like CMV, EBV, BKV …
- Transplantation medicine, autoimmune diseases, cancer …
- Improved immunogenicity / enhanced performance of vaccines
- Enhanced assay sensitivity, e.g. for monitoring immune responses against tumor-associated antigens
- Barabas S et al. (2008). Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein. PLoS Pathog. 4:e1000198. (Read more)
- Barabas S et al. (2017). An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 18:14. (Read more)
- Banas B et al. (2017). Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 18:15. (Read more)
- Reuschel E et al. (2017). Functional impairment of CMV-reactive cellular immunity during pregnancy. J. Med. Virol. 89:324-331. (Read more)
- WO/2010/115984 “METHOD FOR POLYPEPTIDE TRANSFER INTO CELLS”
- WO/2003/080792 “USE OF UREA-ADJUVATED POLYPEPTIDES FOR DIAGNOSIS, PROPHYLAXIS AND TREATMENT”
- WO/2003/046212 “METHOD FOR IDENTIFYING TARGET EPITOPES OF THE T CELL MEDIATED IMMUNE RESPONSE AND FOR ASSAYING EPITOPE-SPECIFIC T CELLS”